Skip to content
Home » Uncategorized » 2013 | October » The Death of the HDL Hypothesis?

The Death of the HDL Hypothesis?

    The shifting sands of time and medical
    research constantly reshape the
    topography of our knowledge landscape.
    For decades we have been trained in
    the descriptions of “good” and “bad”
    cholesterol. Observational data from the
    Framingham Heart Study and others
    convinced us that high-density lipoprotein
    cholesterol (HDL-c) is “good cholesterol”
    and protective to the cardiovascular
    system. We have hypothesized that higher
    the HDL-c level, the more protection is
    conferred and that targeting and raising
    the HDL-c therapeutically will lead to
    primary prevention of cardiovascular
    disease. It appears that it is time for us to
    rethink this hypothesis.
    The results of several recent, largescale investigations have called the HDL-c
    hypothesis into serious doubt. Scrutiny
    of the latest evidence, and a fresh look at
    the older evidence, has prompted several
    authorities to herald that “the HDL
    hypothesis is on the ropes,” and that “this
    is the death knell of niacin, for sure…”1,2
    While these statements are broad and
    over-reaching, our present understanding
    of the HDL-c hypothesis certainly requires
    some revising.
    The inverse association between HDL-c
    and coronary heart disease (CHD) has
    been observed repeatedly throughout
    large-scale studies. Castelli et al, 1988,
    published a now infamous characterization
    of HDL-c and risk from the Framingham
    Heart Study (FHS), which demonstrated
    that for men 50–70 years old, at any level
    of low-density lipoprotein cholesterol
    (LDL-c), HDL-c concentrations less than
    25 mg/dL were associated with the highest
    incidence of CHD. Conversely, at any level
    of LDL-c, HDL-c concentrations greater
    than 65 mg/dL were associated with the
    lowest incidence of CHD.3
    HDL-c is a strong predictor of CHD risk
    in both men and women. The Coronary
    Primary Prevention Trial (CPPT), Multiple
    Risk Factor Intervention Trial (MRFIT),
    Lipid Research Clinics Follow-up Study
    (LRCF), Israeli Ischemic Heart Disease
    Study (IIHDS), FHS, and others have
    demonstrated that HDL-c concentrations
    less than 40 mg/dL are associated with
    approximately double the incidence of
    CHD compared to HDL-c concentrations
    over 50 mg/dL.4
    We have learned from
    these studies that low concentrations of
    HDL-c are our best predictor of CHD.5


    Inconsistent Studies


    The problem with the HDL hypothesis
    is that the medical literature contains
    important inconsistencies with regard to
    it. Extremely low HDL-c is not consistently
    correlated with early CHD, and extremely
    high levels are not consistently protective
    against CHD. More importantly,
    interventional trials repeatedly fail to show
    a cardioprotective benefit from raising
    HDL-c levels in humans. There is a big
    difference between observing that low
    HDL-c is correlated with CHD risk and the
    converse, ie, demonstrating that raising the
    HDL-c decreases the incidence of CHD.
    The announcement of “The death of the
    HDL hypothesis” comes on the heels of the
    failures of 4 large-scale interventional trials
    over recent years, all of which were focused
    on increased HDL-c as a means to lower
    cardiovascular disease (CVD) incidence.
    Cholesteryl ester transfer protein
    (CETP) inhibition has been a target of
    recent pharmaceutical innovation for
    novel lipid modification therapy. CETP
    exchanges triglycerides from VLDL
    and LDL molecules for cholesteryl
    esters from HDL molecules; therefore,
    CETP inhibition should raise HDL-c
    levels and improve CVD morbidity and
    mortality. The ILLUMINATE trial was
    an investigation of the CETP inhibitor,
    torcetrapib, in 15 067 patients at high
    CVD risk.6
    While there was a statistically
    significant increase in HDL-c of 72% over
    baseline levels and decreases in LDL-c
    levels in participants taking torcetrapib,
    the trial had to be stopped prematurely
    due to a statistically significant increased
    risk of cardiovascular events and all-cause
    mortality in the group taking the drug.
    Dalcetrapib, another CETP inhibitor,
    underwent recent clinical investigation
    in the dal-OUTCOMES trial7
    ; 15 871
    patients who had a recent acute coronary
    syndrome were randomized to take either
    dalcetrapib or placebo, in addition to usual
    care. Over 31 months of follow-up, the
    HDL-c levels of patients taking dalcetrapib
    increased 31-40% (compared to 4-11% in
    the placebo group); however, there were
    no significant differences in nonfatal
    myocardial infarctions, ischemic strokes,
    unstable angina, cardiac arrests, or deaths
    from coronary heart disease between the
    two groups.
    The AIM HIGH trial was designed to
    investigate whether using extended-release
    niacin in addition to simvastatin to raise
    low HDL-c was superior to simvastatin,
    alone, in reducing CVD deaths, events,
    hospitalizations, or revascularizations.8
    A
    total of 3414 participants were randomized
    into 2 groups; all received simvastatin
    40-80 mg/day (with or without ezetimibe,
    10 mg/day), to ensure that their LDL-c
    levels remained between 40-80 mg/dL.
    Extended-release niacin, 1500-2000 mg/day,
    was given to 1718 participants, while 1696
    received placebo. Niacin significantly
    increased HDL-c and lowered LDL-c and
    triglycerides compared to placebo over
    the 3-year follow-up. However, there was
    no difference in outcomes between the 2
    groups and the trial was stopped early due
    to lack of efficacy.
    The Heart Protection Study TwoTHRIVE (HPS2-THRIVE) was a very large,
    multinational study which investigated
    extended-release niacin (ERN) in primary
    prevention of major cardiovascular
    events.9
    Participants were randomized
    to take either 2000 mg/day of ERN plus
    laropiprant, 40 mg, or placebo; all 25 673
    patients also took simvastatin with or
    without ezetimibe. After nearly 4 years
    of follow-up, there were no significant
    differences between the 2 groups
    against the composite primary outcome:
    prevention of first myocardial infarction,
    stroke or revascularization. Serious adverse
    events, including diabetic complications,
    new-onset diabetes, infections, myopathies,
    hemorrhages, and others were significantly
    higher in the ERN group.
    Each of the 4 research trials discussed
    above was fraught with problems and
    potential confounders. The problems with
    these trials leave us to ask ourselves and
    the pall bearers of the HDL hypothesis
    whether that hypothesis was tested in these
    trials in the first place. The ILLUMINATE
    and dal-OUTCOMES trials were
    investigations of novel lipid modification
    agents. The expected efficacy of those
    drugs was based on the HDL hypothesis,
    but the trials were not designed to test
    the HDL hypothesis. Their failures and
    adverse events were likely to be the result
    of their novel mechanism-of-action and
    off-target effects, not some failure of the
    HDL hypothesis.
    In the AIM HIGH study, participants
    started the study with baseline LDL-c
    levels of 40-80 mg/dL; in HPS2-THRIVE,
    mean baseline lipid levels were: total
    cholesterol 128 mg/dL, LDL-c 63 mg/dL,
    HDL-c 44 mg/dL. Therefore, we are left
    to wonder whether we should expect to
    see any differences in outcomes between 2
    groups which are already at target LDL-c
    levels, regardless of the type of add-on
    medication. Finally, in HPS2-THRIVE,
    laropiprant was added to extendedrelease niacin as an anti-flushing agent.
    The problem is that laropiprant is a DP1
    receptor antagonist, meaning that it blocks
    the action of prostaglandin D2
    (PGD2
    ) and
    prevents PGD2
    -dependent vasodilation.
    Therefore, its use in the study is a plausible
    confounder, especially as it pertains to
    adverse events in the study.
    Doubts About HDL-C as a
    Therapeutic Target
    The National Lipid Association (NLA) has
    produced a consensus statement on HDL.
    The statement was discussed at the annual
    scientific sessions in May, 2013, and will
    be published in late 2013. Among others,
    these 3 will be prominent: 1) we can no
    longer consider HDL-c a therapeutic target;
    2) HDL cholesterol cannot be considered a
    biomarker of HDL particles (HDL-p); 3) we
    must redouble our efforts to understand
    the HDL particle.10
    We can no longer consider HDL-c to
    be a target of therapy. Simply put, there
    is no evidence behind it. While there are
    important shortcomings and problems with
    the trials that have been conducted, the
    evidence we have is the evidence we have,
    and little of it demonstrates that raising
    HDL-c levels changes cardiovascular risks
    or outcomes.
    Beyond Cholesterol – The
    HDL Particle
    HDL cholesterol is not the same as HDL
    particles. Cholesterol transport is just
    one small part of the action of the HDL
    particle in the body. Too often we refer to
    HDL and LDL and others as “cholesterol,”
    which they are not; they are transport
    molecules which carry several types of
    lipids, proteins and other components,
    depending on their species. It is likely
    that we have missed most of what is
    important about HDL-p because we have
    taken our eye off the ball and focused on
    HDL-c rather than on understanding the
    HDL particle.
    The HDL particle is a complex transport
    molecule in the human body, which we
    have scarcely begun to understand. Peter
    Toth, MD, the president of NLA, presented
    the HDL consensus statement at the
    May 2013 sessions and said, “…The fact
    that there are plausible reasons for why
    these trials failed suggests that the HDL
    hypothesis has still not been tested. For this
    reason, it is far too premature to abandon
    the HDL hypothesis. On the contrary,
    we need much more research in order to
    understand the reason for the unexpected
    results of these failed trials. It is premature
    to abandon the research efforts to better
    elucidate how the modulation of HDL
    metabolism and functionality impacts risk
    for CHD.”5
    We are at the very beginning of our
    understanding of the HDL particle. We
    have incorrectly oversimplified it as
    “good cholesterol” and the vehicle of
    reverse cholesterol transport. The HDL
    molecule is a complex transport molecule
    in the human body. While it does
    transport lipid species, it also transports
    cytokines, messenger RNA, microRNA,
    and others. While it does participate, at
    times, in reverse cholesterol transport,
    it also plays important roles in
    inflammation, gene transcription, and
    cell-to-cell communication that we do
    not fully understand. Put simply, the
    HDL hypothesis is not dead; it may not
    yet have even been fully formed. We
    stand not at the foot of the grave of the
    HDL hypothesis, but on the precipice
    of a journey through a new landscape
    of HDL science and exploration, one on
    which we should now embark with a
    fresh perspective and great excitement

    Your Cart

    No Item Found
    Subtotal $0.00
    Shipping $0.00
    Tax $0.00
    Total $0.00
    0